Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/29172
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRattanathammethee T.
dc.contributor.authorNorasetthada L.
dc.contributor.authorBunworasate U.
dc.contributor.authorWudhikarn K.
dc.contributor.authorJulamanee J.
dc.contributor.authorNoiperm P.
dc.contributor.authorLanamtieng T.
dc.contributor.authorPhiphitaporn P.
dc.contributor.authorNavinpipat M.
dc.contributor.authorKanya P.
dc.contributor.authorJit-ueakul D.
dc.contributor.authorWongkhantee S.
dc.contributor.authorSuwannathen T.
dc.contributor.authorChaloemwong J.
dc.contributor.authorWong P.
dc.contributor.authorMakruasi N.
dc.contributor.authorKhuhapinant A.
dc.contributor.authorPrayongratana K.
dc.contributor.authorNiparuck P.
dc.contributor.authorKanitsap N.
dc.contributor.authorSuwanban T.
dc.contributor.authorIntragumtornchai T.
dc.contributor.otherSrinakharinwirot University
dc.date.accessioned2023-11-15T02:08:04Z-
dc.date.available2023-11-15T02:08:04Z-
dc.date.issued2023
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85159668075&doi=10.1007%2fs00277-023-05273-8&partnerID=40&md5=9299f71f4acc9abd816d0a3d77e96833
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/29172-
dc.description.abstractRelapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has been approved for R/R DLBCL patients. However, real-world data on Pola-based regimens in R/R DLBCL patients, especially in Thailand, are limited. This study aimed to evaluate the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. Thirty-five patients who received Pola-based treatment were included in the study, and their data were compared to 180 matched patients who received non-Pola-based therapy. The overall response rate (ORR) in the Pola group was 62.8%, with complete remission and partial remission rates of 17.1% and 45.7%, respectively. The median progression-free survival (PFS) and overall survival (OS) were 10.6 months and 12.8 months, respectively. The study found a significantly higher ORR in Pola-based salvage treatments compared to non-Pola-based therapy (62.8% vs. 33.3%). The survival outcomes were also significantly superior in the Pola group, with longer median PFS and OS than the control group. Grades 3–4 adverse events (AEs) were mainly hematological, and they were tolerable. In conclusion, this study provides real-world evidence of the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. The results of this study are promising and suggest that Pola-based salvage treatment could be a viable option for R/R DLBCL patients who have limited treatment options. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.subjectDiffuse large B-cell lymphoma
dc.subjectPolatuzumab vedotin
dc.subjectReal-world setting
dc.subjectRefractory
dc.subjectRelapse
dc.titleOutcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationAnnals of Hematology. Vol 102, No.7 (2023), p.1887-1895
dc.identifier.doi10.1007/s00277-023-05273-8
Appears in Collections:Scopus 2023

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.